Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced platelet count in mice protects against glucose intolerance and beta cell loss during a long-term high-fat diet.

Frontiers in immunology·2026
Same author

Large distant deletion disrupts CDKN2A enhancer and predisposes to melanoma.

medRxiv : the preprint server for health sciences·2026
Same author

Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy.

JHEP reports : innovation in hepatology·2026
Same author

From Community Benefits to Vulnerabilities: Reverse-Logic Analysis of Nature-Based Solution Treescapes Across Europe.

International journal of environmental research and public health·2026
Same author

HIRA-mediated H3.3 deposition preserves hepatocyte cell identity during liver aging.

Research square·2026
Same author

The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.

Cell reports·2026

Related Experiment Video

Updated: Jun 16, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma.

Louise van der Weyden1, Martin Del Castillo Velasco-Herrera1, Saamin Cheema1

  • 1Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.

The British Journal of Dermatology
|October 11, 2024
PubMed
Summary

This study reveals key genetic drivers in cutaneous leiomyosarcoma (cLMS), identifying TP53 and RB1 mutations and UV light as potential causes. These findings pave the way for targeted therapies for this rare cancer.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 16, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Genetics
  • Dermatology

Background:

  • Cutaneous leiomyosarcoma (cLMS) is a rare skin cancer originating from dermal smooth muscle cells.
  • Previous genetic studies were limited by small sample sizes, identifying mutations in RB1, TP53, and copy number alterations in MYOCD, IGF1R, and PTEN.

Purpose of the Study:

  • To comprehensively analyze the molecular landscape of cLMS.
  • To identify novel driver events and potential therapeutic targets for cLMS.

Main Methods:

  • Whole-exome sequencing and RNA sequencing were performed on 38 cLMS cases.
  • Retrospective, multi-institutional study design.

Main Results:

  • TP53 and RB1 were confirmed as significantly mutated driver genes.
  • Recurrent mutations suggest ultraviolet light exposure as a potential etiological factor.
  • Identified focal deletions (TP53, KDM6B) and amplifications (ZMYM2, MYOCD, MAP2K4, NCOR1), alongside broad chromosomal alterations and novel gene fusions.

Conclusions:

  • Large-scale molecular analysis is crucial for understanding rare tumors like cLMS.
  • Identified novel driver events and potential therapeutic targets.
  • Findings enable the development of targeted treatments for cLMS, similar to other leiomyosarcoma subtypes.